PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 16441136

Structural and texture evolution with temperature of layered double hydroxides intercalated with paramolybdate anions.

D Carriazo·C Domingo·C Martín·V Rives
View original source ↗Export metadata ↓

Abstract

Paramolybdate-LDHs with MgAl or ZnAl cations within the layers have been prepared by the ion-exchange method from hydrotalcites with different interlayer anions (OH-, NO3(-), and terephthalate). The samples and the oxides obtained after their calcination were characterized by element chemical analysis, PXRD, FT-Raman spectroscopy, thermal analysis (TG/DTA), N2 adsorption at -196 degrees C, and SEM. The results show that layered solids with hydrotalcite-type structure were obtained in which the interlayer space is occupied by heptamolybdate with a small amount of MoO4(2-) units formed through hydrolysis of the polyanion; both oxomolybdenum species undergo a progressive distortion of the octahedral units from 50 degrees C but are roughly stable up to 250 degrees C as a consequence of the interaction between the polyanion and the brucite-like layers. This distortion is responsible for the observed decrease in the height of the gallery for samples heated in the temperature range, 50-250 degrees C, with respect to the original samples. Rehydration of the calcined solids allows recovering of their original structures and the initial values for the gallery heights. Calcination between 300 and 400 degrees C gives rise to a collapse of the layered structure, and amorphous phases are formed, in which molybdenum is both octahedrally and tetrahedrally coordinated. Crystalline magnesium and zinc molybdates (MgMoO4 and ZnMoO4) are formed at 450 and 600 degrees C, respectively. All solids have some microporosity, which decreases with increasing the calcination temperature.

Explore related subjects

Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D Carriazo, C Domingo, C Martín, V Rives. 2006-02-06. Structural and texture evolution with temperature of layered double hydroxides intercalated with paramolybdate anions.. https://doi.org/10.1021/ic0508674

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2027

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗